Stay updated on NanoFlu Vaccine Safety & Immunogenicity Clinical Trial

Sign up to get notified when there's something new on the NanoFlu Vaccine Safety & Immunogenicity Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the NanoFlu Vaccine Safety & Immunogenicity Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:27:53.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a modification in the number of subjects enrolled and randomized into treatment groups in a Phase 1/2 clinical trial evaluating the safety and immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine with Matrix M1 Adjuvant in Healthy Older Adults.
    Difference
    0.1%
    Check dated 2024-06-06T14:24:02.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying the inclusion and exclusion criteria for healthy older adults. Previously, no information was provided under the Participation Criteria section.
    Difference
    34%
    Check dated 2024-05-22T20:32:19.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:43:30.000Z thumbnail image

Stay in the know with updates to NanoFlu Vaccine Safety & Immunogenicity Clinical Trial

Enter your email address, and we'll notify you when there's something new on the NanoFlu Vaccine Safety & Immunogenicity Clinical Trial page.